Atrium iCAST Balloon Expandable Covered Stent; 7mm x 22mm x 120cm; Model/Part Number 85455 (Mark...

FDA Device Recall #Z-2761-2017 — Class II — May 25, 2017

Recall Summary

Recall Number Z-2761-2017
Classification Class II — Moderate risk
Date Initiated May 25, 2017
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Atrium Medical Corporation
Location Hudson, NH
Product Type Devices
Quantity 246 (US: 183 units; Foreign: 63 units)

Product Description

Atrium iCAST Balloon Expandable Covered Stent; 7mm x 22mm x 120cm; Model/Part Number 85455 (Marketed in U.S. only) Atrium Advanta V12 Balloon Expandable Covered Stent; 7mm x 22mm x 120cm; Model/Part Number 85355 (Marketed OUTSIDE U.S. only) The iCAST Covered Stent is indicated for the treatment of tracheobronchial strictures produced by malignant neoplasms.

Reason for Recall

Firm received a complaint that a customer who ordered an ADVANTA V12 7mm x 22mm x 120cm received an ADVANTA v12 7 mm x 38 mm x 80 cm, due to the manifold (catheter hub) was printed as 7mm x 38 mm x 80 cm. The complaint was the result of incorrect dimensional information (7mm x 38mm x 80cm) printed on the manifiold (catheter hub). The complaint device physical dimensions matched the dimensional information displayed on the outer packaging and the device inner pouch. This was the only complaint received for this non-conformance.

Distribution Pattern

Worldwide distribution-US (nationwide) and countries of: Germany, Great Britain, Austria, Ireland, Netherlands, France, Italy, Sweden, and San Marino.

Lot / Code Information

Part Number 85455: Lots 240735, 240523; Part Number 85355: Lot 240734

Other Recalls from Atrium Medical Corporation

Recall # Classification Product Date
Z-0024-2025 Class II iCast Covered Stent, 6MMx16MMx120CM, Model Numb... Sep 9, 2024
Z-1960-2024 Class II ADVANTA VXT, 7X70, 1GDS, NH, STR-SW. Single-End... May 3, 2024
Z-1951-2024 Class II ADVANTA VXT, 5X40, 1GDS, NH, STR-SW. Single-End... May 3, 2024
Z-1989-2024 Class II ADVANTA VXT, 6X80, 1GDS, FH, STR-TW. Single-End... May 3, 2024
Z-1954-2024 Class II ADVANTA VXT, 5X50, 1GDS, NH, STR-SW. Single-End... May 3, 2024

Frequently Asked Questions

Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.

Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.

Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.

What Should You Do?

Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.